NTLA (Intellia Therapeutics) Owner Earnings per Share (TTM): -3.22 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NTLA Intellia Therapeutics Inc NTLA
69 GF Score
Price $13.28
GF Value $13.58
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Intellia Therapeutics Owner Earnings per Share (TTM)?

Intellia Therapeutics NTLA +14.48% 69 Owner Earnings per Share (TTM) is -3.22 as of Jun. 2026. GuruFocus rates NTLA with a GF Score™ of 69/100 and a GF Value™ of $13.58 (Fairly Valued). The stock has 5 warning signs investors should review. Among 208 Biotechnology companies, Intellia Therapeutics ranks worse than 480768.75% on this metric.

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Intellia Therapeutics's Owner Earnings per Share (TTM) ended in Jun. 2026 was $-3.22. It's Price-to-Owner-Earnings ratio for today is 0.


The historical rank and industry rank for Intellia Therapeutics's Owner Earnings per Share (TTM) or its related term are showing as below:



NTLA's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 24.54
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

Intellia Therapeutics's Earnings per Share (Diluted) for the three months ended in Jun. 2026 was $-0.80. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was $-3.36. It's PE Ratio (TTM) ratio for today is At Loss.

Intellia Therapeutics's EPS without NRI for the three months ended in Jun. 2026 was $-0.80. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 was $-3.35. It's PE Ratio without NRI ratio for today is At Loss.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Intellia Therapeutics Owner Earnings per Share (TTM) Related Terms


Intellia Therapeutics Owner Earnings per Share (TTM) Historical Data

* Premium members only.

The historical data trend for Intellia Therapeutics's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intellia Therapeutics Owner Earnings per Share (TTM) Chart

Intellia Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.91 -6.17 -5.99 -5.05 -4.20

Intellia Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.34 -4.75 -4.20 -3.78 -3.22

NTLA vs SEPN, AVBP, VIR: Owner Earnings per Share (TTM) Comparison

For the Biotechnology subindustry, Intellia Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intellia Therapeutics Price-to-Owner-Earnings vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intellia Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Intellia Therapeutics's Price-to-Owner-Earnings falls into.


NTLA
69GF Score
Intellia Therapeutics Inc NTLA
Owner Earnings per Share (TTM) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Intellia Therapeutics Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Intellia Therapeutics's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income -399.98
Depreciation, Depletion and Amortization 15.24
Change In Deferred Tax 0.00
5Y Average of Maintenance Capital Expenditure 16.44
Change In Working Capital -28.11
Shares Outstanding (Diluted Average) 133.48

1. Start with "Net Income" from income statement. Intellia Therapeutics's Net Income for the trailing twelve months (TTM) ended in Jun. 2026 was $-399.98 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Intellia Therapeutics's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Jun. 2026 was $15.24 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Intellia Therapeutics's Change In Deferred Tax for the trailing twelve months (TTM) ended in Jun. 2026 was $0.00 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $16.44 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Intellia Therapeutics's 5-Year Average Maintenance Capital Expenditure = $16.44 Mil

5. "Change In Working Capital" is from cashflow statement. Intellia Therapeutics's Change In Working Capital for the trailing twelve months (TTM) ended in Jun. 2026 was $-28.11 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Intellia Therapeutics's Shares Outstanding (Diluted Average) for the months ended in Jun. 2026 was 133.480 Mil.

Intellia Therapeutics's Onwer Earnings Per Share for Jun. 2026 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( -399.975 +15.235+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-16.444947929534+-28.108)/133.480
=-3.22

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=13.28/-3.22
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Owner Earnings per Share (TTM) of -3.22 mean?
Intellia Therapeutics (NTLA) has a Owner Earnings per Share (TTM) of -3.22 as of Jun. 2026. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Intellia Therapeutics. According to the industry distribution chart, Intellia Therapeutics ranks #999999 out of 208 companies in the Biotechnology industry.
Is Intellia Therapeutics' Owner Earnings per Share (TTM) too high?
Intellia Therapeutics' current Owner Earnings per Share (TTM) is -3.22. Based on the distribution chart, Intellia Therapeutics ranks #999999 out of 208 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Intellia Therapeutics has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Intellia Therapeutics' Owner Earnings per Share (TTM) compare to SEPN and AVBP?
According to the Biotechnology industry distribution chart, Intellia Therapeutics ranks #999999 out of 208 companies for Owner Earnings per Share (TTM). This places Intellia Therapeutics in the lower half of its industry. The industry median Owner Earnings per Share (TTM) is 24.54. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Owner Earnings per Share (TTM) for a Biotechnology company?
The median Owner Earnings per Share (TTM) among Biotechnology companies is 24.54, based on 208 companies in the industry. Companies in the top quartile (top 25%) have a Owner Earnings per Share (TTM) significantly above this median, while those in the bottom quartile fall well below. However, Owner Earnings per Share (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Owner Earnings per Share (TTM) mean?
A high Owner Earnings per Share (TTM) can signal that a stock is expensive relative to its fundamentals. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Intellia Therapeutics. For the Biotechnology industry, the median Owner Earnings per Share (TTM) is 24.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intellia Therapeutics's current Owner Earnings per Share (TTM) is -3.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intellia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Intellia Therapeutics (NTLA) is currently considered Fairly Valued. The stock's GF Value™ is $13.58, compared to a current price of $13.28 — trading 2.2% below its estimated fair value. The current Owner Earnings per Share (TTM) is -3.22. Intellia Therapeutics' overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Owner Earnings per Share (TTM) calculated?
Owner Earnings per Share (TTM) is calculated from a company's financial statements. For Intellia Therapeutics (NTLA), the current Owner Earnings per Share (TTM) is -3.22 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Intellia Therapeutics (NTLA) Overvalued in 2026?

Based on GuruFocus' analysis, Intellia Therapeutics stock appears to be undervalued. The current stock price of $13.28 is trading 2.2% below its estimated GF Value™ of $13.58. GuruFocus considers Intellia Therapeutics to be Fairly Valued.

Key valuation signals for NTLA:

  • Owner Earnings per Share (TTM): -3.22
  • GF Value™: $13.58 vs. price of $13.28 (2.2% below fair value)
  • GF Score™: 69/100 with 5 warning signs

No single metric tells the full story. See the NTLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Intellia Therapeutics Business Description

Other Exchanges 0JBU:UK38I:Germany
Address 40 Erie Street, Suite 130, Cambridge, MA, USA, 02139
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
69GF Score

Get the complete analysis for NTLA

Owner Earnings per Share (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.28
Price
$13.58
GF Value